Summit Therapeutics Inc. (SMMT) Presents at TD Cowen 46th Annual Health Care Conference TranscriptSeeking Alpha • 03/02/26
SMMT Incurs Wider-Than-Expected Q4 Loss, Pipeline Progress in FocusZacks Investment Research • 02/24/26
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025Business Wire • 02/23/26
Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026Business Wire • 02/17/26
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire • 01/30/26
Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI TherapyBusiness Wire • 01/29/26
Summit Therapeutics Inc. (SMMT) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/12/26
Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC)Business Wire • 01/12/26
Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLCBusiness Wire • 01/12/26
Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/06/26
Trading Near Its 52-Week Low, Is Summit Therapeutics a Good Stock to Buy Right Now?The Motley Fool • 12/05/25
Summit Therapeutics Inc. (SMMT) Presents at Evercore 8th Annual Healthcare Conference TranscriptSeeking Alpha • 12/04/25
Summit Therapeutics Inc. (SMMT) Presents at Citi Annual Global Healthcare Conference 2025 TranscriptSeeking Alpha • 12/02/25
Summit Therapeutics Inc. (SMMT) Presents at Jefferies London Healthcare Conference 2025 TranscriptSeeking Alpha • 11/18/25
Summit Therapeutics Inc. (SMMT) Presents at UBS Global Healthcare Conference 2025 TranscriptSeeking Alpha • 11/11/25
Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in ChinaBusiness Wire • 11/07/25
Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025Business Wire • 10/31/25